New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Renren Inc (NYSE:RENN), Zogenix, Inc (NASDAQ:ZGNX), Hemispherx BioPharma, Inc (NYSEMKT:HEB), Camtek LTD (NASDAQ:CAMT)
Renren Inc (NYSE:RENN) the stock opened the session at $3.00 but then moved to $3.02. At that price, the stock showed a positive performance of 0.67%. Renren Inc. operates real name social networking Internet platform in the People’s Republic of China. Its platform enables its users to connect and communicate with each other, share information and user-generated content, play online games, listen to music, shop for deals and a range of other features and services. Its Renren Open Platform program allows users to access applications from third-party developers through an open application programming interface. Its Renren Connect program allows users to sign in and share information and content from over 2,000 Renren Connect partner Websites.
Will RENN Continue To Move Higher? Find Out Here
Zogenix, Inc (NASDAQ:ZGNX) opened the session at $3.47 and closed the session at $3.34. The stock showed a negative performance of -3.19% in previous trading session. Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company’s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate,
Has ZGNX Found The Bottom And Ready To Gain Momentum? Find Out Here
Hemispherx BioPharma, Inc (NYSEMKT:HEB) opened the session at $0.25 and closed the session at $0.231. The stock showed a negative performance of -6.44% in previous trading session. The beta of the stock remained 1.76. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
Why Should Investors Buy HEB After the Recent Fall? Just Go Here and Find Out
Camtek LTD (NASDAQ:CAMT) the stock advanced 3.23% and finished the session at $4.16. Traded with volume of 1.15 million shares in the prior session and the average volume of the stock remained 3.79 million shares. The beta of the stock remained 1.90. Camtek Ltd. (Camtek) designs, develops, manufactures and markets automated solutions dedicated for enhancing production processes and yield for the semiconductor manufacturing and packaging and the printed circuit board (PCB) and integrated circuit (IC) substrate industries. Camtek also designs, develops, manufactures and markets automated optical inspection (AOI), systems and related products. The Company’s AOI systems are used to enhance both production processes and yields for manufacturers in the semiconductor manufacturing and packaging industry and PCB and IC Substrate industry.
Will CAMT Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)